A mixture of low-molecular-weight neuropeptides and free amino acids derived from porcine (pig) brain tissue. Contains fragments that mimic the activity of naturally occurring neurotrophic factors (BDNF, NGF, CNTF). Used in 50+ countries for stroke, TBI, and dementia — but NOT approved in the US.
Cerebrolysin is a unique therapeutic peptide preparation consisting of low-molecular-weight neuropeptides (< 10 kDa) and free amino acids derived from enzymatic breakdown of purified porcine brain proteins. It is manufactured by EVER Neuro Pharma (Austria) and has been used clinically in Europe, Asia, and Latin America since the 1970s.
Unlike the other peptides in this directory, Cerebrolysin is not a single defined sequence but a standardized mixture containing fragments that functionally mimic neurotrophic factors — particularly brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), and ciliary neurotrophic factor (CNTF). Its peptide components are small enough to cross the blood-brain barrier.
Cerebrolysin is unique among peptides on this site: rather than being a single synthetic molecule, it is a standardized mixture of low-molecular-weight neuropeptides and free amino acids derived from porcine (pig) brain tissue through a controlled enzymatic proteolysis process. The mixture contains brain-derived neurotrophic factor (BDNF)-like peptides, nerve growth factor (NGF)-like peptides, and other neurotrophic and neuroprotective fragments that collectively mimic the activity of endogenous neurotrophic factors.
Cerebrolysin has been approved and used clinically in over 50 countries (primarily in Europe, Asia, and Latin America) for the treatment of stroke, traumatic brain injury (TBI), and dementia (including Alzheimer's disease). It is notably NOT approved in the United States. Multiple randomized controlled trials have been conducted, with results showing modest but statistically significant improvements in neurological outcomes after stroke and cognitive function in Alzheimer's patients. However, a 2020 Cochrane review concluded that while Cerebrolysin appeared safe, the quality of evidence for efficacy was low to moderate, and larger, more rigorous trials were needed.
The mechanism involves multi-target neurotrophic support: promoting neuronal survival, enhancing synaptic plasticity, reducing neuroinflammation, and supporting neurogenesis. This multi-target approach is considered both Cerebrolysin's strength (addressing multiple aspects of neurodegeneration simultaneously) and its weakness (difficult to characterize and standardize compared to single-molecule drugs).
Cerebrolysin's peptide fragments are believed to bind to neurotrophin receptors (TrkA, TrkB) and activate downstream signaling cascades identical to those triggered by endogenous neurotrophic factors. The PI3K/Akt pathway promotes neuronal survival by inhibiting apoptosis. The MAPK/ERK pathway drives neuronal differentiation and axonal growth. CREB activation promotes expression of genes involved in synaptic plasticity, long-term potentiation, and memory formation.
| Pathway | Effect | Significance |
|---|---|---|
| Neurotrophic mimicry | Small peptides mimic BDNF, NGF, CNTF signaling | Activates survival and growth pathways in neurons without needing full-size neurotrophins |
| BBB penetration | Peptides < 10 kDa cross the blood-brain barrier | Enables systemic (IV/IM) administration rather than intracerebral injection |
| Anti-apoptotic | Activates PI3K/Akt → inhibits caspase cascade | Protects neurons from ischemic and excitotoxic death |
| Synaptogenesis | Promotes new synaptic connections and dendritic branching | May improve functional recovery after brain injury |
| Neurogenesis | Stimulates neural stem cell proliferation in hippocampus | Potential to generate new neurons in adult brain |
| Study | Design | Findings | Level |
|---|---|---|---|
| Acute ischemic stroke | Multiple RCTs, meta-analyses, n=thousands | Some studies show improved neurological recovery at 90 days. Results inconsistent across trials. A large 2020 Cochrane review found low-certainty evidence of benefit. | Level I (mixed/debated) |
| Alzheimer's disease | RCTs, n=several hundred | Some trials show modest cognitive improvement (ADAS-cog). Not consistently replicated. Not accepted as standard therapy. | Level I-II (modest) |
| Traumatic brain injury | RCTs | Some evidence of improved GCS scores and functional outcome. Sample sizes small. | Level II |
| Vascular dementia | Clinical studies | Used extensively in Eastern Europe and Asia. Some evidence of cognitive benefit. | Level II-III |
Clinical safety record: Cerebrolysin has been administered to millions of patients across 50+ countries with a generally favorable safety profile. The most common adverse effects are dizziness, headache, and injection site reactions. These are typically mild and transient.
Allergic reactions: Because Cerebrolysin is derived from porcine brain tissue, rare allergic reactions can occur. It is contraindicated in patients with known hypersensitivity to porcine proteins. Severe anaphylactic reactions have been reported but are extremely rare.
Seizure risk: Cerebrolysin should be used with caution in patients with epilepsy, as rare cases of seizures have been reported, possibly related to its neurostimulatory effects.
BSE/prion concerns: As a porcine-derived biological product, theoretical concerns about prion disease have been raised. However, pigs are not known to be susceptible to bovine spongiform encephalopathy (BSE), and the manufacturing process includes steps designed to reduce prion risk.
| Jurisdiction | Status |
|---|---|
| FDA | NOT approved. No application submitted. |
| EMA | Not centrally approved, though used in some EU countries. |
| International | Approved and widely used in Austria, Germany, Russia, China, South Korea, and 50+ other countries. |
| Controversy | Western neurologists are generally skeptical due to inconsistent trial results and lack of FDA/EMA approval. Eastern European and Asian neurologists use it routinely. |